Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
Japan Tissue Engineering (J-TEC) has filed for Japanese regulatory approval of its autologous cultured oral mucosal epithelium COMET01 for the treatment of corneal epithelial stem cell deficiency, the Fujifilm group company said on September 14. COMET01 is a cell sheet…
To read the full story
Related Article
- J-TEC’s Ocural, Cell Sheet for Eye Disease, Launched in Japan
December 13, 2021
- J-TEC’s Oral Mucosal Cell Sheet Ocural Earns NHI Listing
September 16, 2021
- Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
June 24, 2021
- Japan Approves J-TEC’s Mucosal Cell Sheet for Corneal Stem Cell Deficiency
June 14, 2021
BUSINESS
- Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
March 31, 2026
- Meiji Pharma Invests in Centivax to Support Vaccine R&D
March 31, 2026
- Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
March 31, 2026
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…